A new US biotech, Aiolos Bio, has drawn in an impressive $245 million in Series A financing that will help it complete clinical testing of lead drug AIO-001 for moderate-to-severe asthma.

Chris So Wai-yin feels the pressure of taking a talented first-starter to the races, but said he was not about to rush things with his gun three-year-old Aiolos. So will unveil the son of Super ...

GSK has taken another step towards rebuilding its respiratory pipeline with a $1.4 billion agreement to buy Aiolos Bio and its lead drug AIO-001 for asthma and other indications. The deal ...